Literature DB >> 21267581

In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction.

Pavel Poredos1, Mateja Kaja Jezovnik.   

Abstract

The aim of this study was to evaluate the levels of anti-inflammatory interleukin-10 and pro-inflammatory cytokines and their relationship to endothelial function in patients with idiopathic venous thrombosis. Forty-nine eligible patients of both sexes with idiopathic venous thrombosis and 48 matched control subjects were studied. Levels of inflammatory markers were determined. Endothelial function was evaluated by ultrasound measurement of the flow mediated dilatation (FMD) of the brachial artery. Compared to the control group, patients with idiopathic venous thrombosis had significantly lower levels of interleukin-10 1.81 pg/ml (1.53-2.21) versus 2.71 pg/ml (1.84-3.65), p < 0.001. Patients also had increased levels of pro-inflammatory cytokines: interleukin-6 2.37 pg/ml (1.59-4.09) versus 2.03 pg/ml (1.49-2.59), p = 0.025, interleukin-8 3.53 pg/ml (2.94-5.30) versus 2.25 pg/ml (1.77-2.90), p < 0.001. Furthermore, decreased FMD was observed in patients: 5.0% (3.9-6.9) versus 12.7% (10.8-15.6), p < 0.001. FMD was related to levels of interleukin-10 (r = 0.33, p = 0.001) and was inversely related to pro-inflammatory cytokines interleukin-6 (r = -0.34, p = 0.001) and interleukin-8 (r = -0.43, p < 0.001). Patients with idiopathic venous thrombosis have decreased levels of IL-10 and increased levels of pro-inflammatory cytokines. This imbalance indicates that in the stable phase of the disease, patients have an increased systemic inflammatory response. This inflammatory response could be the consequence of the disease, but most probably is involved in the pathogenesis of venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21267581     DOI: 10.1007/s00380-010-0111-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  26 in total

Review 1.  The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29.

Authors:  Scott Commins; John W Steinke; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2008-04-11       Impact factor: 10.793

Review 2.  Cytokines and thrombosis.

Authors:  C Dosquet; D Weill; J L Wautier
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

3.  On the combined effect of statins and lycopene on cytokine production by human peripheral blood cells.

Authors:  Michael Bergman; Meir Djaldetti; Hertzel Salman; Hanna Bessler
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 4.  Pathogenesis of venous thrombosis: a new insight.

Authors:  T W Wakefield; R M Strieter; M R Prince; L J Downing; L J Greenfield
Journal:  Cardiovasc Surg       Date:  1997-02

5.  Relation of blunted dilation of the brachial artery in insulin-dependent diabetes mellitus to microalbuminuria.

Authors:  P Poredos; A Kek
Journal:  Am J Cardiol       Date:  2000-08-01       Impact factor: 2.778

6.  Inflammatory response in the acute phase of deep vein thrombosis.

Authors:  Edith M Roumen-Klappe; Martin den Heijer; Stan H M van Uum; Johanna van der Ven-Jongekrijg; Fedde van der Graaf; Hub Wollersheim
Journal:  J Vasc Surg       Date:  2002-04       Impact factor: 4.268

7.  Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study.

Authors:  P H Reitsma; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2004-04       Impact factor: 5.824

8.  Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease.

Authors:  Stephan Fichtlscherer; Susanne Breuer; Christopher Heeschen; Stefanie Dimmeler; Andreas M Zeiher
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

Review 9.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

10.  Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study.

Authors:  Sverre C Christiansen; Inger Anne Naess; Suzanne C Cannegieter; Jens Hammerstrøm; Frits R Rosendaal; Pieter H Reitsma
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

View more
  16 in total

1.  Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism.

Authors:  Qiong-Fang Yang; Ting-Ting Lu; Cai-Min Shu; Lan-Fang Feng; Hao-Teng Chang; Qiao-Ying Ji
Journal:  Exp Ther Med       Date:  2017-08-02       Impact factor: 2.447

2.  Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes.

Authors:  Clara Bambace; Anna Sepe; Elena Zoico; Mariassunta Telesca; Debora Olioso; Sara Venturi; Andrea Rossi; Francesca Corzato; Silvia Faccioli; Luciano Cominacini; Francesco Santini; Mauro Zamboni
Journal:  Heart Vessels       Date:  2013-01-08       Impact factor: 2.037

Review 3.  Biomarkers of deep venous thrombosis.

Authors:  Huacheng Hou; Zhijuan Ge; Pu Ying; Jin Dai; Dongquan Shi; Zhihong Xu; Dongyang Chen; Qing Jiang
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

Review 4.  Pathophysiology of deep vein thrombosis.

Authors:  Simón Navarrete; Carla Solar; Roberto Tapia; Jaime Pereira; Eduardo Fuentes; Iván Palomo
Journal:  Clin Exp Med       Date:  2022-04-26       Impact factor: 3.984

5.  Impact of advanced age on the severity of normotensive pulmonary embolism.

Authors:  Karsten Keller; Johannes Beule; Meike Coldewey; Wolfgang Dippold; Jörn Oliver Balzer
Journal:  Heart Vessels       Date:  2014-06-19       Impact factor: 2.037

6.  The assessment of proinflammatory cytokines in the patients with the history of cerebral venous sinus thrombosis.

Authors:  Farnaz Akbari; Askar Ghorbani; Farzad Fatehi
Journal:  Iran J Neurol       Date:  2016-04-03

7.  Successful reduction of inflammatory responses and arachidonic acid-cyclooxygenase 2 pathway in human pulmonary artery endothelial cells by silencing adipocyte fatty acid-binding protein.

Authors:  Qian Wang; Guanglin Shi; Ying Teng; Xia Li; Jin Xie; Qin Shen; Caixin Zhang; Songshi Ni; Zhiyuan Tang
Journal:  J Inflamm (Lond)       Date:  2017-03-20       Impact factor: 4.981

8.  Monocytes Expose Factor XIII-A and Stabilize Thrombi against Fibrinolytic Degradation.

Authors:  Fahad S M Alshehri; Claire S Whyte; Ahmet Tuncay; Maria-Louise Williams; Heather M Wilson; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-06-19       Impact factor: 5.923

9.  Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism.

Authors:  Sung Hee Lim; Sook-Young Woo; Seonwoo Kim; Young Hyeh Ko; Won Seog Kim; Seok Jin Kim
Journal:  Cancer Res Treat       Date:  2015-03-02       Impact factor: 4.679

Review 10.  COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness.

Authors:  Fenghe Du; Bao Liu; Shuyang Zhang
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.